• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Arch Bio Begins Phase 2 CS-AKI Trial At St. Michael`s Hospital

    GLOBENEWSWIRE

    Arch Bio Scientists Link IL-32 To Inflammation In Diabetic

    GLOBENEWSWIRE

    Arch Bio Appoints Dr. Patrick Vink As Board Chairman

    GLOBENEWSWIRE

    Arch Bio Gets Ethics Approval For St. Michael`s In Phase II

    GLOBENEWSWIRE

    Arch Bio Expands Phase 2 AKI Trial To Include Royal Columbian

    GLOBENEWSWIRE

    Arch Acquires Breakthrough Platform to Develop New CKD Drugs

    GLOBENEWSWIRE

    Arch Biopartners Begins Ph II PONTIAK Trial for Drug-Induced AKI

    GLOBENEWSWIRE

    Arch Biopartners`s Board Approval to Join the Phase II Trial

    GLOBENEWSWIRE

    Arch Biopartners Gets Ethics Approval For Phase II Trial On CS-AKI

    GLOBENEWSWIRE

    Arch Biopartners Doses First Patient in LSALT Phase II Trial

    PHARMABIZ

    Arch Biopartners Gets Approval For LSALT Peptide Phase II Trial In CS-AKI

    GLOBENEWSWIRE

    Arch Biopartners Announces Phase II Trial Approval For LSALT Peptide In CS-AKI

    GLOBENEWSWIRE

    St. Michael`s Hospital Joins LSALT Peptide Phase II Cardiac Surgery AKI Trial

    GLOBENEWSWIRE

    Arch Biopartners Team Publishes Data from Phase II Trial for LSALT Peptide

    GLOBENEWSWIRE

    University of Calgary Joins the Ph II of LSALT Peptide Targeting Kidney Injury

    GLOBENEWSWIRE

    Arch Bio Announces Dosing of First Patient in Phase II Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Receives Health Canada Approval to Conduct PII Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Biop Receives Approval to Proceed with Phase II Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Bio Submits Application to Conduct the Phase II Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Bio Submits Application to Conduct a Phase II Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Biopartners Receives Permission From U.S. FDA to Proceed Phase II AKI Trial

    GLOBENEWSWIRE

    Arch Biopartners Announces +VE Results ofDose Escalation Trial for LSALT Peptide

    GLOBENEWSWIRE

    Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.